Pevion Biotech and CEVEC Pharmaceuticals Sign Exclusive License Option Agreement

28-May-2010 - Germany

Pharmaceuticals announced the signing of an exclusive license option agreement with Pevion Biotech. The agreement enables Pevion Biotech to exclusively use CEVEC’s transient CAP-T™ cell expression technology to manufacture and commercialize a protein antigen for vaccination against a widespread human infectious disease. Following successful entry into toxicological studies and clinical phases I to III, CEVEC will receive undisclosed milestone payments and additional running royalties after market approval. Further financial details of the agreement were not disclosed.

The transient CAP-T™ protein production technology is based on CAP® cells, a human immortalized cell line for stable protein production derived from amniocytes and developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression levels even for difficult to express proteins. They have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns. The platform allows efficient protein production from research, development and scale up to large scale manufacturing in high-volume bioreactors.

“The signing of this agreement is a major milestone for CEVEC since it represents our first exclusively granted license for a clinically highly relevant protein produced in our CAP® cells. We’re proud that Pevion Biotech as one of the most innovative vaccine companies has chosen our CAP® technology expression platform to produce a technically demanding protein that so far remains a challenge to be expressed in standard cells like CHO or HEK 293,” states Rainer Lichtenberger, CEO of CEVEC Pharmaceuticals.

The target protein is part of a vaccine that Pevion Biotech intends to develop based on its proprietary and market-validated virosome technology platform.

https://www.bionity.com/en/news/118168/pevion-biotech-and-cevec-pharmaceuticals-sign-exclusive-license-option-agreement.html